A5090766654- Multiple Myeloma Research and Treatments
- Venous Thromboembolism Diagnosis and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Platelet Disorders and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acute Myeloid Leukemia Research
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Sarcoidosis and Beryllium Toxicity Research
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Cutaneous lymphoproliferative disorders research
- Viral-associated cancers and disorders
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Chronic Lymphocytic Leukemia Research
- Cardiac tumors and thrombi
- Acute Lymphoblastic Leukemia research
- Cancer therapeutics and mechanisms
- Oral Health Pathology and Treatment
- Hematological disorders and diagnostics
- Blood groups and transfusion
Université Jean Monnet
2019-2025
Inserm
2014-2025
Centre Hospitalier Universitaire de Saint-Étienne
2013-2025
SAnté INgenierie BIOlogie Saint-Etienne
2020-2024
Université Claude Bernard Lyon 1
2021-2024
Institute Cancer De La Loire Lucien Neuwirth
2016-2023
Biologie, ingénierie et imagerie pour l'Ophtalmologie
2020-2022
Centre d'Investigation Clinique - Innovation Technologique
2019
Hôpital Nord
2010-2017
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone patients newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) considered the best standard of care (SOC). To improve current SOC, we evaluated added value weekly bortezomib (V) to isatuximab plus (IsaRd versus Isa-VRd). This Intergroupe Francophone Myeloma phase 3 study randomized 270 NDMM were TI, aged 65-79 years, IsaRd Isa-VRd arms. The primary endpoint was a minimal residual...
Venous thromboembolism (VTE) remains a critical issue in the management of patients with multiple myeloma (MM), particularly when immunomodulatory drugs (IMiDs) combined dexamethasone therapy are being prescribed as first-line and relapse therapy. One possible explanation for persistent high rates VTE, is use inappropriate thromboprophylaxis strategies starting antimyeloma treatment. To tackle issue, Intergroupe francophone du myélome (IFM) offered convenient guidance VTE MM initiating...
Aim: To assess the clinical features and outcome of lymphoma when associated with sarcoidosis to determine whether this association gives a better prognosis. Design : Multicentre retrospective cohort study. Methods Retrospective chart review. Results: Twenty-one patients were included (9 males, 12 females). Median age at diagnosis was 48 years (range: 24–68 years). In 14 cases, occurred within previously known sarcoidosis. Five received concomitant lymphoma, whereas preceded in two patients....
Besides peripheral cytopenias, bone marrow abnormalities, such as fibrosis, pure red cell aplasia and aplastic anemia have been reported in patients with systemic lupus erythematosus (SLE), suggesting that may be a 25 target organ SLE.Our objective was to describe this involvement.This registry is nationwide retrospective study. Centers provided data concerning medical history, SLE manifestations, type of hematologic disorder, treatments outcome. Bone aspirations and/or biopsies were...
Ischemic stroke has been reported in various conditions associated with eosinophilia. FIP1L1-PDGFRA fusion ([Fip1-like 1-platelet-derived growth factor receptor alpha]; F/P) leads to the proliferation of eosinophilic lineage and thus a clonal hypereosinophilic syndrome that is highly responsive imatinib.We previously on nationwide retrospective study 151 patients F/P-associated syndrome. Patients from this cohort clinical history ischemic (as well as 2 additional cases) were further analyzed...
Multiple myeloma (MM) is associated with a high risk of thrombosis, particularly during the first months treatment including immunomodulatory drugs (IMiDs). There no consensus on prevention thromboembolic in patients de novo MM, and identification requiring anticoagulant thromboprophylaxis remains challenging. Evaluating coagulability by an vitro thrombin generation (TG) test might be way identifying such patients.To determine whether TG assessment could reveal increase three chemotherapy...
LettersMay 2021JAK1/2 Inhibition in Severe TAFRO Syndrome: A Case ReportMartin Killian, MD, PhD, Sébastien Viel, PharmD, Emilie Chalayer, Fabien Forest, Sylvain Grange, Pierre-Benoit Bonnefoy, Eric Oksenhendler, Pascal Cathébras, and Stéphane Paul, PhDMartin PhDCentre Hospitalier Universitaire de Saint-Etienne Université Jean Monnet, Lyon, Saint-Etienne, France, Lyon Sud, Hospices Civils Pierre-Bénite, PhDInstitut Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, MDCentre PhDHôpital...
Background: BCL-2 inhibition represents a promising therapeutic approach in multiple myeloma (MM). Venetoclax (VEN) is an oral BCL-2-selective BH3 mimetic and currently approved CLL. VEN has shown activity MM cell lines with t(11;14), part because there may be greater co-dependence such clones. safe patients (pts) encouraging clinical activity. should provide novel targeted therapy AL amyloidosis as most of the pts harbored t(11;14). Various retrospective cohorts are now reported alone or...
Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a recent disease concept whose physiopathology remains largely unknown. Association of TAFRO features with immune-mediated or hematologic disorders have been reported but not chronic myelomonocytic leukemia. Chronic leukemia (CMML) myeloproliferative/myelodysplastic that frequently associated autoimmune autoinflammatory features. Herein, we report 2 cases CMML-associated...